The new tuberculosis.

Tuberculosis in Britain today. BMJ (1993) 6.17

Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures. J Clin Microbiol (1993) 4.05

Detection of Mycobacterium tuberculosis in clinical specimens by polymerase chain reaction and Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test. J Clin Microbiol (1993) 4.04

Secular trends of tuberculosis in western Europe. Bull World Health Organ (1993) 3.67

Tuberculosis of the central nervous system. Postgrad Med J (1999) 3.63

Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother (1993) 3.46

Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis (1998) 3.05

Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J Bacteriol (1993) 2.72

Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay. J Clin Microbiol (1999) 2.46

Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother (1994) 2.40

Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (1995) 2.25

Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents Chemother (1994) 2.23

Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev (2011) 2.22

Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother (1996) 2.22

Simple and rapid identification of the Mycobacterium tuberculosis complex by immunochromatographic assay using anti-MPB64 monoclonal antibodies. J Clin Microbiol (1999) 2.14

New York City's tuberculosis control efforts: the historical limitations of the "war on consumption". Am J Public Health (1993) 2.11

Pulmonary tuberculosis: diagnosis and treatment. BMJ (2006) 2.04

The dual epidemics of tuberculosis and AIDS: ethical and policy issues in screening and treatment. Am J Public Health (1993) 1.93

Mutations in the rpoB gene of Mycobacterium tuberculosis that interfere with PCR-single-strand conformation polymorphism analysis for rifampin susceptibility testing. J Clin Microbiol (1997) 1.89

Targeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides. Proc Natl Acad Sci U S A (1996) 1.89

The uraA locus and homologous recombination in Mycobacterium bovis BCG. J Bacteriol (1993) 1.75

Gastroduodenal tuberculosis management guidelines, based on a large experience and a review of the literature. Can J Surg (2004) 1.70

Effects of peroxides on susceptibilities of Escherichia coli and Mycobacterium smegmatis to isoniazid. Antimicrob Agents Chemother (1994) 1.69

Evaluation of the recombinant 38-kilodalton antigen of Mycobacterium tuberculosis as a potential immunodiagnostic reagent. J Clin Microbiol (1997) 1.69

A statistical analysis of the seasonality in pulmonary tuberculosis. Eur J Epidemiol (2000) 1.60

The need for epidemic intelligence. Public Health Rep (1996) 1.35

Susceptibilities of oxyR regulon mutants of Escherichia coli and Salmonella typhimurium to isoniazid. Antimicrob Agents Chemother (1993) 1.33

Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob Agents Chemother (1999) 1.30

Mapping of the delayed-type hypersensitivity-inducing epitope of secreted protein MPT64 from Mycobacterium tuberculosis. Infect Immun (1995) 1.27

Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J Clin Microbiol (2008) 1.26

A species-specific nucleotide sequence of Mycobacterium tuberculosis encodes a protein that exhibits hemolytic activity when expressed in Escherichia coli. Infect Immun (1995) 1.21

Leprosy, tuberculosis, and the new genetics. J Bacteriol (1993) 1.16

Intestinal Co-infection of Tuberculosis and CMV can Cause Massive Lower GI Bleeding in a Patient with HIV. J Surg Sci (2013) 1.14

A single point mutation in the embB gene is responsible for resistance to ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother (1997) 1.07

Preservation of surface lipids and determination of ultrastructure of Mycobacterium kansasii by freeze-substitution. Infect Immun (1994) 1.07

Escalating threat from tuberculosis: the third epidemic. Thorax (1995) 1.06

Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012. BMC Infect Dis (2014) 1.04

Colonic tuberculosis mimicking Crohn's disease: case report. BMC Gastroenterol (2002) 1.03

Colonoscopy evaluation after short-term anti-tuberculosis treatment in nonspecific ulcers on the ileocecal area. World J Gastroenterol (2008) 1.03

Reduced NK activity correlates with active disease in HIV- patients with multidrug-resistant pulmonary tuberculosis. Clin Exp Immunol (1994) 0.99

Disseminated cutaneous infection due to Mycobacterium tuberculosis in a person with AIDS. CMAJ (1993) 0.98

A meta-analysis of drug resistant tuberculosis in Sub-Saharan Africa: how strongly associated with previous treatment and HIV co-infection? Ethiop J Health Sci (2013) 0.97

Tropical respiratory medicine. 2. Impact of human immunodeficiency virus on tuberculosis in developing countries. Thorax (1994) 0.96

Neonatal technology, perinatal survival, social consequences, and the perinatal paradox. Am J Public Health (1995) 0.93

Evaluation of the effect of Humulus lupulus alcoholic extract on rifampin-sensitive and resistant isolates of Mycobacterium tuberculosis. Res Pharm Sci (2012) 0.92

Clinical presentation of abdominal tuberculosis in HIV seronegative adults. BMC Gastroenterol (2005) 0.88

Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis. J Biol Chem (2014) 0.87

Ileoscopy in patients with ileocolonic tuberculosis. World J Gastroenterol (2007) 0.87

Improved diagnosis of central nervous system tuberculosis by MPB64-Target PCR. Braz J Microbiol (2008) 0.84

Peritoneal tuberculosis: diagnostic options. Infect Dis Obstet Gynecol (1999) 0.84

Visceral fat as a useful parameter in the differential diagnosis of Crohn's disease and intestinal tuberculosis. Intest Res (2014) 0.80

Nonlinear pattern of pulmonary tuberculosis among migrants at entry in Kuwait: 1997-2006. BMC Public Health (2008) 0.79

Increasing incidence of tuberculosis in the young and the elderly in Scotland. Thorax (1996) 0.78

Tuberculosis in Lebanese jails: prevalence and risk factors. Eur J Epidemiol (1999) 0.77

Epidemiological aspects of tuberculosis in the Padua Health District 1985-1996. Eur J Epidemiol (1998) 0.76

Topics for our times: the increasing demand for tuberculosis services--a new encumbrance on tuberculosis control programs. Am J Public Health (1997) 0.75

Gastrointestinal tuberculosis is not associated with proton pump inhibitors: a retrospective cohort study. World J Gastroenterol (2013) 0.75

The scourge of tuberculosis revisited. Can J Infect Dis (1995) 0.75

Analysis of DNA gyrA Gene Mutation in Clinical and Environmental Ciprofloxacin-Resistant Isolates of Non-Tuberculous Mycobacteria Using Molecular Methods. Jundishapur J Microbiol (2016) 0.75

The bacterial and host factors associated with extrapulmonary dissemination of Mycobacterium tuberculosis. Front Biol (Beijing) (2015) 0.75

An ethA-ethR-deficient Mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence in vivo, which correlate with altered mycolic acid composition. Infect Immun (2014) 0.75

Antituberculosis: synthesis and antimycobacterial activity of novel benzimidazole derivatives. Biomed Res Int (2013) 0.75

Re-emergence of tuberculosis. BMJ (1993) 0.75

Statewide survey of laboratories performing Mycobacterium tuberculosis testing in Minnesota. Public Health Rep (1996) 0.75

Notification of tuberculosis in a university hospital. Eur J Epidemiol (1998) 0.75

Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med (1992) 8.15

Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA (1995) 15.26

Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med (1991) 8.98

Nationwide survey of drug-resistant tuberculosis in the United States. JAMA (1994) 6.14

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med (1994) 5.66

Public health policy for preventing violence. Health Aff (Millwood) (1993) 5.17

Tuberculosis in the United States. JAMA (1989) 5.12

Rapid drug-susceptibility testing of Mycobacterium tuberculosis. Am Rev Respir Dis (1981) 4.77

Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA (1994) 4.44

Multidrug-resistant tuberculosis. Ann Intern Med (1992) 4.06

The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis (1987) 3.48

Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis (1982) 3.38

Rapid radiometric methods to detect and differentiate Mycobacterium tuberculosis/M. bovis from other mycobacterial species. Am Rev Respir Dis (1984) 3.25

Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida. Ann Intern Med (1984) 3.25

Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis (1978) 3.15

Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis (1990) 2.81

Tuberculosis morbidity in the United States: final data, 1990. MMWR CDC Surveill Summ (1991) 2.53

Epidemiology of tuberculosis in the United States. Epidemiol Rev (1989) 2.23

Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA (1986) 2.18

Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis (1979) 2.15

The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis (1979) 2.13

Tuberculosis in the 1980s. N Engl J Med (1980) 2.09

The relationship between tuberculosis and silicosis. Am Rev Respir Dis (1978) 1.89

The tuberculin skin test. Am Rev Respir Dis (1982) 1.75

Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland. Am Rev Respir Dis (1982) 1.69

The prevalence of tuberculosis and drug resistance among Haitians. N Engl J Med (1982) 1.68

Current tuberculosis screening practices. Am J Public Health (1984) 1.67

The usefulness of phage typing Mycobacterium tuberculosis isolates. Am Rev Respir Dis (1984) 1.58

Acquired immunodeficiency syndrome and extrapulmonary tuberculosis in the United States. Arch Intern Med (1990) 1.57

Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis (1985) 1.56

Extrapulmonary tuberculosis in Oklahoma, 1965 to 1973. Am Rev Respir Dis (1975) 1.54

The epidemiology of tuberculosis in the United States. Semin Respir Infect (1989) 1.52

Treatment of tuberculosis during pregnancy. Am Rev Respir Dis (1980) 1.46

Tuberculosis and acquired immunodeficiency syndrome--Florida. Arch Intern Med (1989) 1.45

The need for epidemic intelligence. Public Health Rep (1996) 1.35

Bacille Calmette-Guérin vaccinations and tuberculin skin tests. JAMA (1985) 1.33

Tuberculosis diagnosed at death in the United States. Chest (1991) 1.31

A continuing survey of tuberculosis primary drug resistance in the United States: March 1975 to November 1977. A United States Public Health Service cooperative study. Am Rev Respir Dis (1978) 1.25

Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial. Am Rev Respir Dis (1984) 1.25

Tuberculosis control among homeless populations. Arch Intern Med (1988) 1.21

Drug-resistant tuberculosis. Am Rev Respir Dis (1991) 1.20

U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis (1979) 1.20

Pyridoxine supplementation during isoniazid therapy. Tubercle (1980) 1.18

The global threat of drug-resistant tuberculosis. N Engl J Med (1998) 1.17

The epidemiology of tuberculosis in the United States. Implications for diagnosis and treatment. Clin Chest Med (1989) 1.16

Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. MMWR Recomm Rep (1990) 1.16

Association between HTLV-III/LAV infection and tuberculosis in Zaire. JAMA (1986) 1.15

Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis (1980) 1.14

Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep (1989) 1.13

Enhancing patient compliance with tuberculosis therapy. Clin Chest Med (1989) 1.13

Tuberculosis and the acquired immunodeficiency syndrome. Chest (1986) 1.11

Tuberculin skin testing of hospital employees: infection, "boosting," and two-step testing. Am J Infect Control (1984) 1.10

The good news and the bad news about multidrug-resistant tuberculosis. Clin Infect Dis (1995) 1.09

Congenital complete heart block associated with hydrops fetalis. J Pediatr (1977) 1.07

Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. JAMA (1985) 1.07

Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis (1984) 1.07

Drug resistance among previously treated tuberculosis patients, a brief report. Am Rev Respir Dis (1980) 1.05

How much tuberculosis in children must we accept? Am J Public Health (1986) 1.04

Assessing prevention effectiveness using data to drive program decisions. Public Health Rep (1994) 1.03

An assessment of the possible association of isoniazid with human cancer deaths. Am Rev Respir Dis (1977) 1.01

Boosting of tuberculin sensitivity among Southeast Asian refugees. Am J Respir Crit Care Med (1994) 1.01

Tuberculosis and gastrectomy. Chest (1985) 1.01

Emetic food poisoning caused by Bacillus cereus. Arch Intern Med (1981) 1.01

Transmission of multiple drug-resistant tuberculosis: report of a school and community outbreak. Am J Epidemiol (1981) 0.97

Recurrent tuberculosis: why do patients develop disease again? A United States Public Health Service cooperative survey. Am J Public Health (1988) 0.95

Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics (1983) 0.94

A continuing survey of primary drug resistance in tuberculosis, 1961 to 1968. A U.S. Public Health Service cooperative study. Am Rev Respir Dis (1976) 0.94

Incentives to take up health services. Lancet (1986) 0.92

The Ottawa County project: a report of a tuberculosis screening project in a small mining community. Am J Public Health (1979) 0.90

Standard therapy for tuberculosis 1985. Chest (1985) 0.90

Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis (1987) 0.90

Adenylate cyclase activity in lymphocyte subcellular fractions. Characterization of non-nuclear adenylate cyclase. Biochem J (1977) 0.89

United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide. Tubercle (1987) 0.89

Prevention and the reforming U.S. health care system: changing roles and responsibilities for public health. Annu Rev Public Health (1996) 0.89

Reorientation of tuberculosis control programmes in the USA. Bull Int Union Tuberc Lung Dis (1989) 0.88

Physician noncompliance with tuberculosis preventive measures. Am Rev Respir Dis (1987) 0.88

Reactivation of tuberculosis in Oklahoma: 1970-1973. Chest (1975) 0.87

Organization and activities of local public health department in Alabama. Ala J Med Sci (1983) 0.87

Congenital tuberculosis. Tubercle (1984) 0.87

The Resource-Based Relative Value Scale: a methodological and policy evaluation. JAMA (1988) 0.87

Decision analysis for isoniazid preventive therapy: take it or leave it? Am Rev Respir Dis (1988) 0.87

Preventive therapy with isoniazid for "inactive" tuberculosis. Chest (1978) 0.86

Federal scene. Introducing Annals of Epidemiology Federal scene section. Ann Epidemiol (1996) 0.85

Should women taking antituberculosis drugs breast-feed? Arch Intern Med (1984) 0.85

The new environment for health services research: private and public sector opportunities. Health Serv Res (1997) 0.85

Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment. Am Rev Respir Dis (1981) 0.84

Prostaglandins and asthma. Ann Intern Med (1973) 0.84

GIS and public health policy: a new frontier for improving community health. J Public Health Manag Pract (1999) 0.82

Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial. Am Rev Respir Dis (1980) 0.82

The incidence of cancer among participants in controlled, randomized isoniazid preventive therapy trial. Am J Epidemiol (1980) 0.80

Letter: Lower lymphocyte cyclic-AMP levels after aspirin. N Engl J Med (1975) 0.80

Urinary tract cancer and isoniazid. Am Rev Respir Dis (1977) 0.79

Rifampin and red urine. JAMA (1977) 0.79

Tuberculosis and body build. JAMA (1987) 0.78

Preventive therapy for tuberculous infection: an intervention in need of improvement. Am Rev Respir Dis (1984) 0.78

Tuberculin skin testing and the HIV epidemic. JAMA (1992) 0.77

Norwalk virus outbreak at a college campus. South Med J (1986) 0.77

Financing health care: a view from the White House. Health Aff (Millwood) (1989) 0.77

An on-line hybrid computing system for dynamic respiratory response studies. Comput Biomed Res (1971) 0.77

HCFA's agenda for promoting high-quality care. Health Aff (Millwood) (1988) 0.76

An attempt to eradicate silicotuberculosis in Ottawa County, Oklahoma. Am J Public Health (1982) 0.75